<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001096.v1.p1" parentStudy="phs001096.v1.p1" createDate="2016-03-28" modDate="2016-07-19">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>David Altshuler</td><td>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, 			MA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Michael Boehnke</td><td>University of Michigan, Ann Arbor, MI</td></tr>
		<tr><td>Principal Investigators</td><td>Mark McCarthy</td><td>Wellcome Trust Centre for Human Genetics, Oxford, UK</td></tr>
		<tr><td>Principal Investigators</td><td>Jose Florez</td><td>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA; Massachusetts General Hospital, Boston, MA, USA</td></tr>
		<tr><td>Sequencing Institute</td><td>The Broad Institute of Harvard and MIT</td><td>Cambridge, MA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>T2D-GENES Multi-Ethnic Exome Sequencing Study: KARE</StudyNameEntrez>
	<StudyNameReportPage>Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Multi-Ethnic Samples (T2D-GENES) Project 1: KARE</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>T2D-GENES (Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Multi-Ethnic Samples) is a NIDDK-funded international research consortium which seeks to identify genetic variants for type 2 diabetes (T2D) through multiethnic sequencing studies. T2D-GENES Project 1 is a multi-ethnic sequencing study designed to assess whether less common variants play a role in T2D risk and to assess similarities and differences in the distribution of T2D risk variants across ancestry groups. </p> <p>The individuals were obtained from 14 cohorts that are listed in Table 1. The strategy was to perform deep exome sequencing of 12,940 individuals, 6,504 with T2D and 6,436 controls, divided among five ancestry groups: Europeans, East Asians, South Asians, American Hispanics, and African Americans. Sequencing was performed at the Broad Institute using the Agilent v2 capture reagent on Illumina HiSeq machines. Please note that while we summarize the full sample list in publications and below, the Kooperative Gesundheitsforschung in der Region Augsburg (KORA) study does not have a sub study, as it is not consented to be deposited in dbGAP.</p> <p> <p><b>Table 1.</b> T2D-GENES Whole Exome Sequencing Studies</p> <table border="1"> <tr> <th><b>Ancestry</b></th> <th><b>Study</b></th> <th><b>Countries of Origin</b></th> <th><b># Cases</b></th> <th><b># Controls</b></th> </tr> <tr> <td>African American</td> <td>Jackson Heart Study</td> <td>US</td> <td>502</td> <td>527</td> </tr> <tr> <td>African American</td> <td>Wake Forest School of Medicine Study</td> <td>US</td> <td>518</td> <td>532</td> </tr> <tr> <td>East Asian</td> <td>Korea Association Research Project</td> <td>Korea</td> <td>526</td> <td>561</td> </tr> <tr> <td>East Asian</td> <td>Singapore Diabetes Cohort Study; Singapore Prospective Study Program</td> <td>Singapore (Chinese)</td> <td>486</td> <td>592</td> </tr> <tr> <td>European</td> <td>Ashkenazi</td> <td>US, Israel</td> <td>506</td> <td>352</td> </tr> <tr> <td>European</td> <td>Metabolic Syndrome in Men Study (METSIM)</td> <td>Finland</td> <td>484</td> <td>498</td> </tr> <tr> <td>European</td> <td>Finland-United States Investigation of NIDDM Genetics (FUSION) Study</td> <td>Finland</td> <td>472</td> <td>476</td> </tr> <tr> <td>European</td> <td>Kooperative Gesundheitsforschung in der Region Augsburg (KORA)</td> <td>Germany</td> <td>97</td> <td>90</td> </tr> <tr> <td>European</td> <td>UK Type 2 Diabetes Genetics Consortium (UKT2D)</td> <td>UK</td> <td>322</td> <td>320</td> </tr> <tr> <td>European</td> <td>Malm&#246;-Botnia Study</td> <td>Finland, Sweden</td> <td>478</td> <td>443</td> </tr> <tr> <td>Hispanic</td> <td>San Antonio Family Heart Study, San Antonio Family Diabetes/ Gallbladder Study, Veterans Administration Genetic Epidemiology Study, and the Investigation of Nephropathy and Diabetes Study Family Component</td> <td>US</td> <td>272</td> <td>219</td> </tr> <tr> <td>Hispanic</td> <td>Starr County, Texas</td> <td>US</td> <td>749</td> <td>704</td> </tr> <tr> <td>South Asian</td> <td>London Life Sciences Population Study (LOLIPOP)</td> <td>UK (Indian Asian)</td> <td>530</td> <td>538</td> </tr> <tr> <td>South Asian</td> <td>Singapore Indian Eye Study</td> <td>Singapore (Indian Asian)</td> <td>563</td> <td>585</td> </tr> </table> <p>The Korea Association Research Project (KARE) studies contributed 526 cases and 561 controls to T2D-GENES Project 1.</p> </p>]]>
	</Description>
	<StudyInEx><![CDATA[
Cases were ascertained according to the following criteria: <ul> <li>Past history of T2D.</li> <li>Use of T2D medication.</li> <li>Fasting plasma glucose &#62;/=7 mmol/l or plasma glucose &#62;/=11.1 mmol/l 2 hours after ingestion of 75gm oral glucose load.</li> <li>Age of disease onset &#62;/=40 years.</li> <li>Participants with early onset and family history prioritized.</li> </ul> <br/>Controls were determined according to the following criteria: <ul> <li>No past history of diabetes.</li> <li>No anti-diabetic medication.</li> <li>Fasting plasma glucose &#60;5.6 mmol/l and plasma glucose 2 hours after ingestion of 75g oral glucose load &#60;7.8 mmol/l at both baseline and follow up timepoints.</li> <li>Older subjects with normal glucose prioritized.</li> </ul> <p>Samples with age of diagnosis &#60;40 excluded.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="27398621"/>
		</Publication>
		<Publication>
			<Pubmed pmid="25625282"/>
		</Publication>
		<Publication>
			<Pubmed pmid="24584071"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Diabetes Mellitus, Type 2"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>David Altshuler</AttName>
			<Institution>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, 			MA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Michael Boehnke</AttName>
			<Institution>University of Michigan, Ann Arbor, MI</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Mark McCarthy</AttName>
			<Institution>Wellcome Trust Centre for Human Genetics, Oxford, UK</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Jose Florez</AttName>
			<Institution>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA; Massachusetts General Hospital, Boston, MA, USA</Institution>
		</Header>
		<Header title="Sequencing Institute">
			<AttName>The Broad Institute of Harvard and MIT</AttName>
			<Institution>Cambridge, MA, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>U01DK085526 (Multiethnic Study of Type 2 Diabetes Genes)</AttName>
			<Institution>National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>U54HG003067 (Large Scale Sequencing and Analysis of Genomes)</AttName>
			<Institution>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="T2D-GENES" url="http://t2d-genes.sph.umich.edu/"/>
	</StudyURLs>
	<StudyHistory><![CDATA[
<p>T2D-GENES (Type 2 Diabetes Genetic Exploration by Next-generation Sequencing in Multi-Ethnic Samples) is a NIDDK-funded international research consortium which seeks to identify genetic variants for type 2 diabetes (T2D) through multiethnic sequencing studies. The organizations involved in the NIDDK U01 include: Broad Institute, University of Michigan, University of Oxford, NIDDK/NIH, University of Chicago, Texas Biomedical Research Institute, Massachusetts General Hospital, University of Texas Health Science Center, University of North Carolina, Blood Systems Research Institute, and University of Mississippi Medical Center.</p> <p>The T2D-GENES collaboration effort consists of 3 projects:</p> <ol> <li>Project 1 seeks to assess whether less common variants play a role in T2D risk and to assess similarities and differences in the distribution of T2D risk variants across ancestry groups. </li> <li>Project 2 is focused on the role of rare and private variants on T2D risk, and is based on deep whole genome sequencing of ~600 members of 20 Mexican American pedigrees. Pedigree members are extensively phenotyped and have been genotyped with Illumina GWAS chips.</li> <li>Project 3 seeks to determine whether multiethnic GWAS meta-analysis might assist in fine-mapping T2D association signals by strengthening evidence for T2D association and narrowing the association interval. Project 3 has focused initially on analysis of five T2D loci chosen as likely candidates for success of this approach.</li> </ol> <p>This submission reflects the activities that occurred in T2D-GENES Project 1. Each of the studies involved in T2D-GENES Project1 are part of larger cohorts. While each participating cohort has specific cohort information and history, that information is not summarized here as we have specifically selected these samples for type 2 diabetes research as part of the T2D-GENES study. For more information on these studies, please see table 2.</p> <p><b>Table 2.</b> Studies contributing samples to T2D-GENES Project 1</p> <p> <table border="1"> <tr> <th><b>Study Name</b></th> <th><b>PI(s)</b></th> <th><b>Study URL (if available)</b></th> </tr> <tr> <td>Jackson Heart Study Candidate Gene Association Resource</td> <td>Jim Wilson</td> <td><a href="//www.jacksonheartstudy.org">http://www.jacksonheartstudy.org</a></td> </tr> <tr> <td>Wake Forest Study</td> <td>Donald Bowden</td> <td></td> </tr> <tr> <td>Korea Association Research Project (KARE) and Korean National Institute of Health (KNIH)</td> <td>Jong-Young Lee and Yoon Shin Cho</td> <td></td> </tr> <tr> <td>Singapore Diabetes Cohort Study and Singapore Prospective Study Program</td> <td>Daniel Ng Peng Keat and Tai E. Shyong</td> <td><a href="http://www.nus-cme.org.sg/about.html">http://www.nus-cme.org.sg/about.html</a></td> </tr> <tr> <td>Longevity Genes in Founder Populations (Ashkenazi)</td> <td>Nir Barzilai, Gil Atzmon</td> <td><a href="//www.einstein.yu.edu/centers/aging/longevity-genes-project/">http://www.einstein.yu.edu/centers/aging/longevity-genes-project/</a></td> </tr> <tr> <td>Metabolic Syndrome in Men Study</td> <td>Markku Laakso</td> <td><a href="//www.nationalbiobanks.fi/index.php/studies2/10-metsim">http://www.nationalbiobanks.fi/index.php/studies2/10-metsim</a></td> </tr> <tr> <td>San Antonio Mexican American Family Studies, Texas</td> <td>Ravindranath Duggirala</td> <td></td> </tr> <tr> <td>Starr County, Texas</td> <td>Craig Hanis</td> <td></td> </tr> <tr> <td>London Life Sciences Population (LOLIPOP)</td> <td>Jaspal Kooner</td> <td><a href="//www.lolipopstudy.org/">http://www.lolipopstudy.org/</a></td> </tr> <tr> <td>Singapore Indian Eye Study</td> <td>Wong Tien Yin</td> <td><a href="//www.seri.com.sg/key-programmes/singapore-epidemiology-of-eye-diseases-seed/">http://www.seri.com.sg/key-programmes/singapore-epidemiology-of-eye-diseases-seed/</a></td> </tr> </table> </p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-T2D-IRB-RD" longName="Disease-Specific (Type 2 Diabetes, IRB, RD)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIDDK</DacName>
      <DacFullName>NIDDK Central Repository GWAS Data Access Committee</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001096.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001096.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001096.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Type 2 Diabetes, IRB, RD)</ConsentName>
        <ConsentAbbrev>DS-T2D-IRB-RD</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Type 2 Diabetes and related disorders.
Requestor must provide documentation of local IRB approval.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
